PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).

about

PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).

Item

http://www.wikidata.org/entity/Q36157118

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@ast

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@en

type

Item

label

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@ast

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@en

prefLabel

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@ast

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@en

P1476

PRognostic factor of Early Dea ...... ion criterion? (PREDIT model).

@en

P2093

Antoine Italiano

http://www.w3.org/2001/XMLSchema#string

Damien Joly

http://www.w3.org/2001/XMLSchema#string

Louis Letinier

http://www.w3.org/2001/XMLSchema#string

Pauline Bosco-Lévy

http://www.w3.org/2001/XMLSchema#string

Sophie Cousin

http://www.w3.org/2001/XMLSchema#string

Stéphanie Hoppe

http://www.w3.org/2001/XMLSchema#string

Thomas Grellety

http://www.w3.org/2001/XMLSchema#string

P2860

Direct regulation of TWIST by HIF-1alpha promotes metastasis

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy

P2888

s12885-016-2819-7

P304

768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2819-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simone Mathoulin-Pélissier

Nicolas Penel

P577

2016-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052122305

http://www.w3.org/2001/XMLSchema#string

P698

27716199

http://www.w3.org/2001/XMLSchema#string

P921

life expectancy

phase II clinical trial

P932

5050995

http://www.w3.org/2001/XMLSchema#string